Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Merrimack Pharmaceuticals Inc.
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2000
Status: Out of Business
BioCentury | Sep 10, 2024
Management Tracks
Vir names Jason O’Byrne CFO
Plus: Maslowski to become CEO of Forge as Miller steps down, and updates from Sofinnova Partners, Abingworth, PATH and more
BioCentury | Feb 9, 2024
Management Tracks
Terns names Amy Burroughs CEO
Plus: Disc hires Jean Franchi as CFO, promotes Jonathan Yu to COO, and updates from Domain, Enable Injections and Alchemab
BioCentury | Nov 9, 2022
Product Development
Ipsen pancreatic cancer readout sets up reward for Merrimack shareholders’ patience
Effectively non-operational since 2019, the biotech could receive milestones tied to Onivyde and pay them out as a dividend
BioCentury | Nov 17, 2021
Management Tracks
Rhee steps down as CEO of Korea’s SCM
Recludix, Ankyra unveil venture rounds and new execs; plus ImmunoGen, Talis, Kira, Sonoma, Spruce, Ankyra and more
BioCentury | Oct 29, 2021
Product Development
Bicycle Therapeutics on a roll
Bicycle is planning to parlay clinical proof of concept for its bicyclic-toxin conjugates into new technologies and product deals
BioCentury | Aug 19, 2020
Management Tracks
Rao to head Sobi R&D; plus new CMOs for Ikena, Agile, Nordic Nanovector and more
Swedish Orphan Biovitrum AB (SSE:SOBI) said Ravi Rao will succeed Milan Zdravkovic as head of R&D, effective Sept. 1. Rao joins the rare diseases company from Aeglea BioTherapeutics Inc.
BioCentury | Jul 23, 2020
Emerging Company Profile
Elevation debuts with tumor-agnostic mAb in Phase II
Elevation Oncology’s lead program is in development for NRG1 fusion-driven solid tumors
BioCentury | Dec 11, 2019
Company News
Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more
BioCentury | Sep 5, 2019
Company News
Management tracks: Locana, Synlogic, Farcast, Oncology Venture, Cala, Novaremed, Sidley Austin and Logos Capital
BioCentury | Jul 10, 2019
Company News
Yumanity’s Coles picks Merrimack, Onyx alum Peters to lead company to the clinic
Items per page:
1 - 10 of 236